<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054781</url>
  </required_header>
  <id_info>
    <org_study_id>2008-12-005</org_study_id>
    <nct_id>NCT01054781</nct_id>
  </id_info>
  <brief_title>Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the complete response (CR) rate after Intensified&#xD;
      1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL and</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall response rate of R+R-CHOP</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of overall response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of the R+R-CHOP combination treatment.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the progression free survival.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore prognostic or predictive biomarkers</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>1st cycle R+R-CHOP 2-8th cycle R-CHOP</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Histologically confirmed CD20 positive Diffuse Large B-cell Lymphoma (DLBCL)&#xD;
&#xD;
          2. Advanced stage: stage III, IV and/or bulky disease (largest diameter ≥ 10.0 cm)&#xD;
             regardless of stage&#xD;
&#xD;
          3. Previously untreated.&#xD;
&#xD;
          4. Performance status: ECOG 0-2.&#xD;
&#xD;
          5. Age ≥ 18&#xD;
&#xD;
          6. At least one or more bidimensionally measurable lesion(s)&#xD;
&#xD;
               -  ≥ 2 cm by conventional CT&#xD;
&#xD;
               -  ≥ 1 cm by spiral CT&#xD;
&#xD;
               -  skin lesion (photographs should be taken) ≥ 2 cm&#xD;
&#xD;
               -  measurable lesion by physical examination ≥ 2 cm&#xD;
&#xD;
          7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically&#xD;
             significant abnormalities&#xD;
&#xD;
          8. Adequate renal function: serum creatinine level &lt; 2 mg/dL (177 μmol/L)&#xD;
&#xD;
          9. Adequate liver functions:&#xD;
&#xD;
               -  Transaminase (AST/ALT) &lt; 3 X upper normal value (or &lt; 5 x ULN in the presence of&#xD;
                  DLBCL involvement of the liver)&#xD;
&#xD;
               -  Bilirubin &lt; 2 X upper normal value (or &lt; 5 x ULN in the presence of DLBCL&#xD;
                  involvement of the liver)&#xD;
&#xD;
         10. Adequate hematological function: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥&#xD;
             1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow&#xD;
             involvement by lymphoma&#xD;
&#xD;
         11. Life expectancy ≥ 6 months&#xD;
&#xD;
         12. A negative serum or urine pregnancy test prior to treatment must be available both for&#xD;
             pre menopausal women and for women who are &lt; 1 years after the onset of menopause.&#xD;
&#xD;
         13. Informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Other subtypes NHL than DLBCL&#xD;
&#xD;
          2. Patients who transformed follicular lymphoma or other indolent lymphoma&#xD;
&#xD;
          3. Primary Central Nervous System (CNS) DLBCL;&#xD;
&#xD;
          4. CNS involvement by lymphoma or any evidence of spinal cord compression. Brain CT/MRI&#xD;
             is only mandatory (within 4 weeks) in case of clinical suspicion of CNS involvement by&#xD;
             lymphoma. Patients who have only had prophylactic intrathecal chemotherapy against CNS&#xD;
             disease are eligible.&#xD;
&#xD;
          5. Patients with a known history of HIV seropositivity or HCV (+). Patients who have HBV&#xD;
             (+) are eligible. However, primary prophylaxis using antiviral agents (i.e.&#xD;
             lamivudine) is recommended for HBV carrier to prevent HBV reactivation during whole&#xD;
             treatment period.&#xD;
&#xD;
          6. Any other malignancies within the past 5 years except curatively treated non-melanoma&#xD;
             skin cancer or in situ carcinoma of cervix uteri&#xD;
&#xD;
          7. Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          8. Other serious illness or medical conditions&#xD;
&#xD;
               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
                  prior to study entry&#xD;
&#xD;
               -  History of significant neurological or psychiatric disorders including dementia&#xD;
                  or seizures&#xD;
&#xD;
               -  Active uncontrolled infection (viral, bacterial or fungal infection)&#xD;
&#xD;
               -  Other serious medical illnesses&#xD;
&#xD;
          9. Known hypersensitivity to any of the study drugs or its ingredients (i.e.,&#xD;
             hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human&#xD;
             antibodies)&#xD;
&#xD;
         10. Concomitant administration of any other experimental drug under investigation, or&#xD;
             concomitant chemotherapy, hormonal therapy, or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WonSeog Kim, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>WonSeog Kim , M.D., PhD.</name_title>
    <organization>Samsung Medical Center,Division of Hematology-Oncology</organization>
  </responsible_party>
  <keyword>Diffuse Large B-Cell Lymphoma (DLBCL)</keyword>
  <keyword>rituximab</keyword>
  <keyword>CHOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

